Septerna (NASDAQ:SEPN) Releases Earnings Results, Beats Expectations By $0.14 EPS

Key Points

• Septerna beat quarterly expectations: The clinical-stage biotech reported an adjusted loss of $0.29 per share, $0.14 better than the expected $0.43 loss. Revenue reached $26.75 million, exceeding the $19.22 million consensus estimate.
• Shares remain near their 52-week high: SEPN traded at $38.85, compared with a 52-week range of $10.62 to $40.65, giving the company a market capitalization of approximately $1.75 billion.
• Analysts are broadly bullish, but insiders have been selling: The stock carries a “Moderate Buy” consensus rating and an average price target of $45.89, while insiders sold 47,828 shares worth about $1.58 million over the past quarter.

Septerna (NASDAQ:SEPN - Get Free Report) released its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14, FiscalAI reports. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million.

Septerna Stock Performance

Shares of SEPN stock traded up $0.02 on Monday, hitting $38.85. The company's stock had a trading volume of 275,426 shares, compared to its average volume of 346,380. Septerna has a fifty-two week low of $10.62 and a fifty-two week high of $40.65. The stock's 50 day moving average is $34.40 and its 200-day moving average is $29.02. The company has a market capitalization of $1.75 billion, a PE ratio of -47.96 and a beta of 2.29.

Analyst Upgrades and Downgrades

SEPN has been the subject of several recent analyst reports. Truist Financial increased their price objective on Septerna from $35.00 to $43.00 and gave the company a "buy" rating in a report on Wednesday, July 1st. Stifel Nicolaus started coverage on Septerna in a research report on Friday, May 1st. They issued a "buy" rating and a $43.00 price objective for the company. Raymond James Financial boosted their target price on Septerna from $47.00 to $53.00 and gave the stock a "strong-buy" rating in a report on Monday, June 8th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Septerna in a research report on Wednesday, July 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Septerna has an average rating of "Moderate Buy" and an average price target of $45.89.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,334 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,323,321.64. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares of the company's stock, valued at $27,897.74. This represents a 73.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 47,828 shares of company stock valued at $1,584,314. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its position in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after purchasing an additional 104,394 shares during the last quarter. ADAR1 Capital Management LLC increased its position in Septerna by 38.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company's stock worth $22,130,000 after purchasing an additional 329,264 shares in the last quarter. First Light Asset Management LLC bought a new position in Septerna in the 4th quarter valued at approximately $17,308,000. Finally, VR Adviser LLC lifted its stake in Septerna by 13.0% in the 3rd quarter. VR Adviser LLC now owns 610,808 shares of the company's stock valued at $11,489,000 after purchasing an additional 70,355 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source